KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Equity Ratio: 2009-2025

Historic Equity Ratio for Halozyme Therapeutics (HALO) over the last 15 years, with Sep 2025 value amounting to 0.23.

  • Halozyme Therapeutics' Equity Ratio rose 6.14% to 0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.23, marking a year-over-year increase of 6.14%. This contributed to the annual value of 0.18 for FY2024, which is 264.64% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Equity Ratio is 0.23, which was up 40.03% from 0.16 recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Equity Ratio ranged from a high of 0.24 in Q3 2021 and a low of 0.04 during Q1 2023.
  • In the last 3 years, Halozyme Therapeutics' Equity Ratio had a median value of 0.15 in 2024 and averaged 0.14.
  • Its Equity Ratio has fluctuated over the past 5 years, first tumbled by 82.70% in 2023, then skyrocketed by 264.64% in 2024.
  • Over the past 5 years, Halozyme Therapeutics' Equity Ratio (Quarterly) stood at 0.18 in 2021, then crashed by 48.29% to 0.09 in 2022, then slumped by 47.56% to 0.05 in 2023, then soared by 264.64% to 0.18 in 2024, then increased by 6.14% to 0.23 in 2025.
  • Its Equity Ratio was 0.23 in Q3 2025, compared to 0.16 in Q2 2025 and 0.22 in Q1 2025.